| |
HR (95% CI)
|
p value
|
|---|
|
Composite endpoint
|
|
Stanniocalcin-2a
|
2.06 (1.13–3.75)
|
0.018
|
|
IGFBP-4a
|
1.73 (1.14–2.64)
|
0.010
|
|
Killip–Kimball class III–IV
|
1.40 (1.13–1.74)
|
0.002
|
|
NT-ProBNPa
|
1.21 (1.07–1.37)
|
0.002
|
|
Age
|
1.06 (1.04–1.08)
|
< 0.001
|
|
LVEF
|
0.97 (0.95–0.98)
|
< 0.001
|
|
All-cause mortality
|
|
Stanniocalcin-2a
|
2.23 (1.16–4.29)
|
0.017
|
|
Killip–Kimball class II–IV
|
1.64 (1.30–2.08)
|
< 0.001
|
|
NT-ProBNPa
|
1.18 (1.02–1.36)
|
0.028
|
|
Age
|
1.07 (1.05–1.10)
|
< 0.001
|
|
LVEF
|
0.97 (0.95–0.99)
|
0.002
|
|
Readmission due to heart failure
|
|
Stanniocalcin-2a
|
3.42 (1.22–9.60)
|
0.020
|
|
Prior myocardial infarction
|
2.85 (1.32–6.16)
|
0.008
|
|
Diabetes mellitus
|
2.36 (1.22–4.58)
|
0.011
|
|
Female sex
|
2.21 (1.15–4.28)
|
0.018
|
|
Age
|
1.04 (1.01–1.07)
|
0.005
|
|
LVEF
|
0.94 (0.92–0.97)
|
< 0.001
|
- IGFBP-4 insulin-like growth factor binding protein-4, LVEF left ventricular ejection fraction
- aHRs (95% CIs) are reported per 1-SD increment of natural log-transformed plasma levels
